Tapemark Competitors and Similar CompaniesClear all
Tapemark's competitors and similar companies include Hansoh Pharma, Catalent, PPD and WuXi Biologics.
 Tapemark Tapemark (also known as LTS Therapy Systems) is a company specializing in the development and manufacturing of transdermal, oral thin film, and unit dose semi-solid drug delivery. |  Catalent Catalent is a company that develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, vaccines, and consumer health products. |  PPD PPD (Pharmaceutical Product Development) is a company that provides drug development and laboratory solutions. |  WuXi Biologics WuXi Biologics (药明生物) is a company operating as an open-access technology platform for biologics drug development. | ||
Founding Date | Founding Date 1952 | Founding Date 1995 | Founding Date 2007 | Founding Date 1985 | Founding Date 2010 |
Type | Type Subsidiary | Type Public | Type Subsidiary | Type Subsidiary | Type Public |
Tags | |||||
Locations | Locations Saint Paul, US HQ | Locations Shanghai, CN HQ | Locations Bridgewater, US HQ Buenos Aires, AR Bruxelles, BE Charleroi, BE Charleroi, BE Charleroi, BE Indaiatuba, BR see more | Locations Wilmington, US HQ Buenos Aires, AR Melbourne, AU Brussels, BE Zaventem, BE São Paulo, BR São Paulo, BR see more | Locations Wuxi, CN HQ George Town, KY Wuppertal, DE Hong Kong, HK Dundalk, IE Cranbury, US King Of Prussia, US |
Employees | Employees 522% decrease | Employees 8,989 | Employees 12,6955% increase | Employees 24,5842% decrease | Employees 12,575 |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) $4.4b (FY, 2024) | Revenue (est.) $4.7b (FY, 2020) | Revenue (est.) ¥21.8b (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods N/A | Cost of goods $3.4b (FY, 2024) | Cost of goods $1.7b (FY, 2020) | Cost of goods ¥10b (FY, 2025) |
Gross profit | Gross profit N/A | Gross profit N/A | Gross profit $953m (FY, 2024) | Gross profit $3b (FY, 2020) | Gross profit ¥12b (FY, 2025) |
Net income | Net income N/A | Net income N/A | Net income ($1b) (FY, 2024) | Net income $160.6m (FY, 2020) | Net income ¥5.7b (FY, 2025) |
Operating ⚠ | |||||
Backlog | Backlog N/A | Backlog N/A | Backlog $2.5b (FY, 2023) | Backlog $9.5b (Q3, 2021) | Backlog $18.5b (H1, 2022) |
Countries | Countries N/A | Countries N/A | Countries 80 (FY, 2023) | Countries 46 (FY, 2020) | Countries N/A |
For sources of this data, please see the company profile
View Company Profiles
Hansoh Pharma
HQ
Shanghai, CN
Employees
8,989
Hansoh Pharmaceutical Group (翰森制药集团总) is a biopharmaceutical company.
View companyCatalent
HQ
Bridgewater, US
Catalent is a company that develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, vaccines, and consumer health products.
View companyPPD
HQ
Wilmington, US
PPD (Pharmaceutical Product Development) is a company that provides drug development and laboratory solutions.
View companyWuXi Biologics
HQ
Wuxi, CN
Employees
12,575
WuXi Biologics (药明生物) is a company operating as an open-access technology platform for biologics drug development.
View company